US EditionDr Boreham's Crucible: If things line up, this biotech's versatility could see it age like fine wine
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Dr Boreham's Crucible: If things line up, this biotech's versatility could see it age like fine wine
Universal Biosensors (ASX:UBI) is well into commercial phase and is thus ‘grown up’, but chairman Graham McLean acknowledges the company has struggled to reach adulthood and produce consistent returns. “Progress has always been slower than expected,” he said in a recent letter to shareholders. “[This is] due to entrenched customer habits, limited awareness, regulatory delays and competitive market environments.” The company this week signalled i…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
